drug · small molecule
RINVOQ LQ
updated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.
targets
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2Non-receptor tyrosine-protein kinase TYK2Tyrosine-protein kinase JAK3
all catalysts(0)
nothing on the calendar yet
Trials studying RINVOQ LQ
- phase2Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
- phase3A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- phase3Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- phase2A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
- phase3A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
- —Expanded Access to Upadacitinib
- phase3Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- phase3A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that